|
Characteristic
| |
Low dose (n = 60)
|
Intermediate dose (n = 77)
|
High dose (n = 222)
|
|---|
|
Gender
|
Females
|
27 (45.0%)
|
30 (50.6%)
|
98 (44.1%)
|
| |
Males
|
33 (55.0%)
|
47 (49.4%)
|
124 (55.9%)
|
|
Age [y]
|
Median
|
51.1
|
55.4
|
59.0
|
| |
Range
|
18.1-77.0
|
21.9-80.5
|
20.5-81.1
|
|
Disease Duration [y]
|
Median
|
1.9
|
1.4
|
1.9
|
| |
Range
|
0.1-25.8
|
0.1-18.6
|
0.1-27.5
|
|
Pretreatment
|
Surgery
|
35 (58.3%)
|
36 (46.8%)
|
125 (56.3%)
|
| |
Chemotherapy
|
14 (23.3%)
|
16 (20.8%)
|
38 (17.1%)
|
| |
Radiation
|
21 (35.0%)
|
31 (40.3%)
|
72 (32.4%)
|
|
Extent
|
Single Metastasis
|
3 (5.0%)
|
11 (14.3%)
|
28 (12.6%)
|
| |
Liver Metastases
|
48 (80.0%)
|
62 (80.5%)
|
189 (85.1%)
|
| |
Bone Metastases
|
16 (26.7%)
|
17 (22.1%)
|
47 (21.2%)
|
|
Creatinine [μmol/L]
|
Median
|
63
|
71
|
69
|
| |
Range
|
22-258
|
26-138
|
33-369
|
|
Tumor Uptake
|
Score 1
|
5 (8.3%)
|
10 (13.0%)
|
18 (8.1%)
|
| |
Score 2
|
6 (10.0%)
|
8 (10.4%)
|
11 (5.0%)
|
| |
Score 3
|
49 (81.7%)
|
59 (76.6%)
|
193 (87.0%)
|
|
Kidney Uptake
|
Score 0
|
2 (3.3%)
|
3 (3.9%)
|
11 (5.0%)
|
| |
Score 1
|
4 (6.6%)
|
8 (10.4%)
|
20 (0.2%)
|
| |
Score 2
|
12 (20.0%)
|
10 (13.0%)
|
52 (23.4%)
|
| |
Score 3
|
42 (70.0%)
|
55 (71.4%)
|
137 (61.7%)
|
|
Histology
|
Carcinoid
|
19 (31.7%)
|
38 (49.4%)
|
106 (47.7%)
|
| |
PNET
|
15 (25.0%)
|
21 (17.3%)
|
64 (28.8%)
|
| |
Rare NET
|
17 (28.3%)
|
9 (11.7%)
|
26 (11.7%)
|
| |
Unknown Primary
|
9 (15.0%)
|
9 (11.7%)
|
26 (11.7%)
|
- PNET: pancreatic neuroendocrine tumors, NET: neuroendocrine tumors, Rare NET include: medullary thyroid cancers, neuroblastomas, phaeochromocytomas, paragangliomas, small cell lung cancers and Merkel cell cancers.
